Sumitomo Pharma Co., Ltd.
SMDPY · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $23,635,000 | -$314,929,000 | -$96,714,000 | $40,600,000 |
| Dep. & Amort. | $25,562,000 | $37,765,000 | $41,263,000 | $38,348,000 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $0 | $0 | $0 | $0 |
| Change in WC | -$18,770,000 | -$95,847,000 | $34,878,000 | -$33,733,000 |
| Other Non-Cash | -$13,927,000 | $131,118,000 | $32,510,000 | -$13,976,000 |
| Operating Cash Flow | $16,500,000 | -$241,893,000 | $11,937,000 | $31,239,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$8,498,000 | -$15,730,000 | -$12,742,000 | -$13,494,000 |
| Net Acquisitions | $1,458,000 | $8,605,000 | $30,172,000 | -$3,701,000 |
| Inv. Purchases | -$1,645,000 | -$4,772,000 | -$6,247,000 | -$25,905,000 |
| Inv. Sales/Matur. | $108,491,000 | $34,499,000 | $10,068,000 | $19,472,000 |
| Other Inv. Act. | -$52,000 | $10,434,000 | $31,168,000 | $5,350,000 |
| Investing Cash Flow | $99,754,000 | $33,036,000 | $52,419,000 | -$18,278,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$112,485,000 | $84,000,000 | $65,499,000 | -$4,931,000 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | -$3,000 | -$2,792,000 | -$11,125,000 | -$11,126,000 |
| Other Fin. Act. | $3,652,000 | -$3,357,000 | -$201,191,000 | -$5,369,000 |
| Financing Cash Flow | -$108,836,000 | $77,851,000 | -$146,817,000 | -$21,426,000 |
| Forex Effect | -$177,000 | $15,440,000 | $24,090,000 | $17,751,000 |
| Net Chg. in Cash | -$5,931,000 | -$114,431,000 | -$59,506,000 | $9,286,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $29,047,000 | $143,478,000 | $202,984,000 | $193,698,000 |
| End Cash | $23,116,000 | $29,047,000 | $143,478,000 | $202,984,000 |
| Free Cash Flow | $3,470,000 | -$257,623,000 | -$805,000 | $17,745,000 |